<DOC>
	<DOCNO>NCT00526617</DOCNO>
	<brief_summary>This Phase I clinical trial study side effect best dose ABT-888 give together Temozolomide ( chemotherapy ) treat patient solid tumor , include metastatic melanoma ( MM ) , BRCA deficient breast , ovarian , primary peritoneal , fallopian tube cancer , hepatocellular carcinoma ( HCC ) .</brief_summary>
	<brief_title>A Phase I Study ABT-888 Combination With Temozolomide Cancer Patients</brief_title>
	<detailed_description>A Phase 1 , multicenter , dose-escalation study evaluate safety tolerability PARP inhibitor ABT-888 combination Temozolomide ( TMZ ) subject non-hematologic malignancy ( NHM ) , include metastatic melanoma ( MM ) , BRCA deficient breast , ovarian , primary peritoneal , fallopian tube cancer , hepatocellular carcinoma ( HCC ) .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Veliparib</mesh_term>
	<criteria>Dose escalation expand safety cohort Evaluable disease , histologically confirm malignancy ( metastatic unresectable ) standard curative measure therapy may provide clinical benefit exist longer effective ECOG Performance Score less equal 2 Adequate hematologic , renal hepatic function Normal sodium , calcium magnesium level Voluntarily sign informed consent Expanded Safety Cohorts Only Population : Metastatic melanoma ( MM ) Hepatocellular carcinoma ( HCC ) Child Pugh Category A B classification BRCA deficient tumor status* : advanced breast cancer ( soft tissue disease ) , advanced ovarian cancer , advance primary peritoneal cancer , advance fallopian tube cancer* *Patients must histologically cytologically confirm solid tumor positive genetic test result document BRCA 1 BRCA 2 mutation status , consider eligible . Serial tumor biopsy : Required subject enrol one Expanded Low Dose Safety Cohorts . Dose Escalation Expanded Safety Cohorts Known central nervous system ( CNS ) metastases CNS primary cancer . Previous current malignancy site , except : adequately treat situ carcinoma cervix uterus ; basal/squamous cell carcinoma skin ; previous malignancy consider cure . Previous history current seizure disorder . Clinically significant uncontrolled major medical condition ( ) medical condition place subject unacceptably high risk toxicity . Transplant recipient patient receive combination antiretroviral therapy HIV due use immunosuppressant therapy . Lactating pregnant female . Chemotherapy , immunotherapy , radiotherapy , biologic investigational therapy allow within either 4 week , 5 half life target therapy prior study drug administration ( Study Day 1 ) . Prior therapy regimens contain dacarbazine ( DTIC ) TMZ permit . Anticancer therapy permit treatment portion study . Hormone therapy , bisphosphonates LHRHagonists prostate cancer permit prior study . Significant adverse event toxicity due previous anticancer treatment recover within one grade level ( exceed Grade 2 ) baseline . Expanded Safety Cohorts Only : MM Only : Prior treatment DNA damaging agent cytotoxic chemotherapy include carboplatin , cisplatin , fotemustine , paclitaxel , vincristine , TMZ DTIC . Prior therapy biologic agent ( include IL2 , interferon , bevacizumab , vaccine immunostimulants ) signal transduction inhibitor ( include sorafenib , erlotinib , sutent elesclomol ) allow . Lower Dose Expanded Safety Cohorts Only Anticoagulant restriction subject tumor biopsy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Solid Tumor</keyword>
	<keyword>Melanoma</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>Ovarian cancer</keyword>
	<keyword>Primary peritoneal cancer</keyword>
	<keyword>Fallopian tube cancer</keyword>
	<keyword>Hepatocellular carcinoma</keyword>
	<keyword>HCC</keyword>
	<keyword>BRCA deficient</keyword>
	<keyword>BRCA mutation</keyword>
	<keyword>Temozolomide</keyword>
	<keyword>Temodar</keyword>
	<keyword>TMZ</keyword>
	<keyword>ABT-888</keyword>
	<keyword>PARP inhibitor</keyword>
</DOC>